It is estimated that patented drugs worth $85 billion in potential annual sales in the U.S. would be off patent during the period 2014-2020. Price competitiveness and manufacture of these generic drugs in the most cost-efficient manner would be the key drivers boosting the prospects of the Indian players, as India is known to have…